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                                                          ABSTRACT 
 
Breast cancer is characterized by a high degree of heterogeneity in terms of histological, 
molecular and clinical features, affecting disease progression and treatment response. The 
cancer stem cell (CSC) model suggests, that cancers are organized in a hierarchical fashion 
and driven by small subsets of CSCs, endowed with the capacity for self-renewal, 
differentiation, tumorigenicity, invasiveness and therapeutic resistance. The overall aim of 
this thesis was to characterize CSC phenotypes and the cellular organization in estrogen 
receptor α + (ERα+) and ERα- subtypes of breast cancer at the individual cell level. 
Furthermore, we aimed to identify novel functional CSC markers in a subtype-independent 
manner, allowing for better identification and targeting of breast-specific CSCs. 
 At present, single-cell quantitative reverse transcription polymerase chain reaction represents 
the most commonly applied method to study transcript levels in individual cells. Inherent to 
most single-cell techniques is the difficulty to analyze minute amounts of starting material, 
which most often requires a preamplification step to multiply transcript copy numbers in a 
quantitative manner. In Paper I we have evaluated effects of variations of relevant 
parameters on targeted cDNA preamplification for single-cell applications, improving 
reaction sensitivity and specificity, pivotal prerequisites for accurate and reproducible 
transcript quantification. 
In Paper II we have applied single-cell gene expression profiling in combination with three 
functional strategies for CSC enrichment and identified distinct CSC/progenitor clusters in 
ERα+ breast cancer. ERα+ tumors display a hierarchical organization as well as different 
modes of cell transitions. In contrast, ERα- breast cancer show less prominent clustering but 
share a quiescent CSC pool with ERα+ cancer. This study underlines the importance of taking 
CSC heterogeneity into account for successful treatment design. 
In Paper III we have used a non-biased genome-wide screening approach to identify 
transcriptional networks specific to CSCs in ERα+ and ERα- subtypes. CSC-enriched models 
revealed a hyperactivation of the mevalonate metabolic pathway. When detailing the 
mevalonate pathway, we identified the mevalonate precursor enzyme 3-hydroxy-3-
methylglutaryl-CoA synthase 1 (HMGCS1) as a specific marker of CSC-enrichment in ERα+ 
and ERα- subtypes, highlighting HMGCS1 as a potential gatekeeper for dysregulated 
mevalonate metabolism important for CSC-features. Pharmacological inhibition of HMGCS1 
could therefore be a novel treatment approach for breast cancer patients targeting CSCs. 
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